Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity scores, changes in foveal thickness measured with optical coherence tomography, and complications of treatment were evaluated.Results: In each monthly measurement, in the BRVO group, foveal thickness decreased from baseline statistically significantly from baseline (p 0.05) and compared with preinjection values, increase ETDRS score at all months was not statistically significant (p>0.05).Conclusion: Treatment of macular edema secondary to BRVO with intravitreal injection of bevacizumab in the early stages was effective and reliable
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Objective: The aim of the present study was to investigate changes in short-term visual acuity and foveal thickness after single-dose intravitreal bevacizumab treatments for macular edema secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).Methods: The patients were separated into 2 groups: 18 eyes of 18 patients with BRVO, and 10 eyes of 10 patients with CRVO.
📊
Key Findings & Data:Objective: The aim of the present study was to investigate changes in short-term visual acuity and foveal thickness after single-dose intravitreal bevacizumab treatments for macular edema secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).Methods: The patients were separated into 2 groups: 18 eyes of 18 patients with BRVO, and 10 eyes of 10 patients with CRVO.
💡
Conclusion & Impact:Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity scores, changes in foveal thickness measured with optical coherence tomography, and complications of treatment were evaluated.Results: In each monthly measurement, in the BRVO group, foveal thickness decreased from baseline statistically significantly from baseline (p 0.05) and compared with preinjection values, increase ETDRS score at all months was not statistically significant (p>0.05).Conclusion: Treatment of macular edema secondary to BRVO with intravitreal injection of bevacizumab in the early stages was effective and reliable
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Objective: The aim of the present study was to investigate changes in short-term visual acuity and foveal thickness after single-dose intravitreal bevacizumab treatments for macular edema secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).Methods: The patients were separated into 2 groups: 18 eyes of 18 patients with BRVO, and 10 eyes of 10 patients with CRVO. Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity scores, changes in foveal thickness measured with optical coherence tomography, and complications of treatment were evaluated.Results: In each monthly measurement, in the BRVO group, foveal thickness decreased from baseline statistically significantly from baseline (p 0.05) and compared with preinjection values, increase ETDRS score at all months was not statistically significant (p>0.05).Conclusion: Treatment of macular edema secondary to BRVO with intravitreal injection of bevacizumab in the early stages was effective and reliable
🔖
Cite This Article
AYYILDIZ, T., CALLI, Ü., ŞALKACI, O., KANDEMİR, B., ÖZERTÜRK, Y. (2017). Short-Term Results After Single-Dose Intravitreal Bevacizumab Treatment for Macular Edema Secondary to Central and Branch Retinal Vein Occlusions. Southern Clinics of Istanbul Eurasia, Cilt: 28 - Sayı: 3, 184–189. https://ajindex.com/articles/314133
Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644–50
Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012;119:1184–9
Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for macular edema seco ndary to branch retinal vein occlusion. Retina 2011;31:1856–62
Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594–602
Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041–9
Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429–37.e7
Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802–9
Chen HC, Wiek J, Gupta A, Luckie A, Kohner EM. Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 1998;82:162–7
Bavbek T, Yenice O, Toygar O. Problems with attempted chorioretinal venous anastomosis by laser for nonischemic CRVO and BRVO. Ophthalmologica 2005;219:267–71
Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C. The natural course of central retinal vein occlusion. Am J Ophthalmol 1990;110:118–23
Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 1997;115:486–91
Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs C